Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

TGX-221

Catalog No: tcsc0110

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
663619-89-4

Formula:
$C_{21}H_{24}N_4O_2$

Pathway:
PI3K/Akt/mTOR

Target:
PI3K

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
364.44

Product Description

TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the **PI3K p110β** catalytic subunit, used for cancer

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

treatment.

IC50 & Target: IC50: 8.5 nM (p110β), 211 nM (p110δ)[5]

In Vitro: TGX-221, BL05 and BL05-HA show selective cytotoxicity to LNCaP cells, which may be due to the deficiency of PTEN in this cell line and the accumulation of PIP3 in the cells[1]. TGX-221 (1 μM) does not affect the expression and phosphorylation of AMPK in C2C12 myoblasts[2]. TGX221 (0.1, 1, 10 μM) induces IL-6 release from ASM cells[2]. TGX-221 does not affect neurotensin-stimulated Akt phosphorylation when used alone, but it further suppresses neurotensin-stimulated phosphorylation of Akt when combined with gefitinib. TGX-221 abolishes the neurotensin-stimulated phosphorylation of Akt in Panc-1 cells[3].

In Vivo: TGX-221 (TGX221, 2.5 mg/kg i.v.) abolishes cyclic flow reductions in a Folts-like carotid artery stenosis preparation of thrombosis, without changing bleeding time, heart rate, blood pressure or carotid vascular conductance[4].